Related Experiment Videos
Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy
1Department of Neuroimmunology, Montreal Neurological Hospital and Institute, McGill University, Quebec, Canada.
Abstract:
Previous reports by our group and by others have shown that in vitro treatment of T cells derived from healthy, normal subjects with interferon beta-1b (IFN-beta1b) reduces metalloproteinase (metalloproteinase type 9 [MMP-9]) activity with a consequent reduction in lymphocyte migration. In this study, we used a Boyden chamber assay to assess the migratory capacity of T cells derived from multiple sclerosis patients who either did or did not receive IFN-beta1b. Lymphocytes derived from patients treated for less than 2 years with IFN-beta migrated at a low rate that was indistinguishable from that of cells isolated from healthy donors. However, longer term treatment with IFN (>3.5 years) was associated with a reversion of the migration to a high level that did not differ statistically from that of cells isolated from untreated multiple sclerosis patients. For both high-migratory groups, migration could be reduced to control levels after the exogenous addition of TIMP-1, a relatively specific inhibitor of the MMP-9, implicating this protease in the process of T-cell migration. Our findings suggest that one of the mechanisms by which IFN-beta exerts its action is by reducing MMP-9 activity and thus the entry of inflammatory cells into the nervous system and, as such, MMPs may constitute potential therapeutic targets in inflammatory diseases such as multiple sclerosis.
Insights
Interferon beta-1b (IFN-beta1b) initially reduces T cell migration in multiple sclerosis patients by inhibiting metalloproteinase-9 (MMP-9). However, long-term treatment may reverse this effect, suggesting MMPs as potential therapeutic targets.
Area of Science:
- Neuroimmunology
- Molecular Medicine
- Cell Biology
Background:
- Interferon beta-1b (IFN-beta1b) is a treatment for multiple sclerosis (MS).
- IFN-beta1b has been shown to reduce metalloproteinase-9 (MMP-9) activity and T cell migration in vitro.
- The effect of long-term IFN-beta1b treatment on T cell migration in MS patients is not fully understood.
Purpose of the Study:
- To investigate the effect of IFN-beta1b treatment duration on T cell migratory capacity in multiple sclerosis patients.
- To elucidate the role of MMP-9 in T cell migration in the context of MS and IFN-beta1b therapy.
Main Methods:
- Boyden chamber assay used to assess T cell migration.
- Analysis of T cells from multiple sclerosis patients with varying durations of IFN-beta1b treatment.
- Exogenous addition of TIMP-1 (tissue inhibitor of metalloproteinase-1) to evaluate MMP-9 involvement.
Main Results:
- Short-term IFN-beta1b treatment (<2 years) reduced T cell migration to levels comparable to healthy donors.
- Long-term IFN-beta1b treatment (>3.5 years) was associated with a return to high T cell migration rates, similar to untreated MS patients.
- MMP-9 inhibition using TIMP-1 reduced high migratory rates in both treated and untreated MS patient groups.
Conclusions:
- IFN-beta1b's mechanism in MS may involve reducing MMP-9 activity, thereby limiting inflammatory cell infiltration into the nervous system.
- Prolonged IFN-beta1b treatment might lead to a loss of its inhibitory effect on T cell migration.
- Matrix metalloproteinases (MMPs) represent potential therapeutic targets for managing inflammatory diseases like multiple sclerosis.